169 related articles for article (PubMed ID: 26433969)
1. Expression and immunogenic characterization of recombinant gp350 for developing a subunit vaccine against Epstein-Barr virus.
Wang M; Jiang S; Han Z; Zhao B; Wang L; Zhou Z; Wang Y
Appl Microbiol Biotechnol; 2016 Feb; 100(3):1221-1230. PubMed ID: 26433969
[TBL] [Abstract][Full Text] [Related]
2. Expression, purification, and immunogenic characterization of Epstein-Barr virus recombinant EBNA1 protein in Pichia pastoris.
Wang M; Jiang S; Liu X; Wang Y
Appl Microbiol Biotechnol; 2013 Jul; 97(14):6251-62. PubMed ID: 23685476
[TBL] [Abstract][Full Text] [Related]
3. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
Front Immunol; 2018; 9():932. PubMed ID: 29765376
[TBL] [Abstract][Full Text] [Related]
4. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
Cui X; Snapper CM
Front Immunol; 2021; 12():734471. PubMed ID: 34691042
[TBL] [Abstract][Full Text] [Related]
5. Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine.
Jackman WT; Mann KA; Hoffmann HJ; Spaete RR
Vaccine; 1999 Feb; 17(7-8):660-8. PubMed ID: 10067671
[TBL] [Abstract][Full Text] [Related]
6. A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine.
Cui X; Cao Z; Sen G; Chattopadhyay G; Fuller DH; Fuller JT; Snapper DM; Snow AL; Mond JJ; Snapper CM
Vaccine; 2013 Jun; 31(30):3039-45. PubMed ID: 23665339
[TBL] [Abstract][Full Text] [Related]
7. Computer-Aided Design of an Epitope-Based Vaccine against Epstein-Barr Virus.
Alonso-Padilla J; Lafuente EM; Reche PA
J Immunol Res; 2017; 2017():9363750. PubMed ID: 29119120
[TBL] [Abstract][Full Text] [Related]
8. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
Perez EM; Foley J; Tison T; Silva R; Ogembo JG
Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
[TBL] [Abstract][Full Text] [Related]
9. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.
Zhang X; Zhao B; Ding M; Song S; Kang Y; Yu Y; Xu M; Xiang T; Gao L; Feng Q; Zhao Q; Zeng MS; Krummenacher C; Zeng YX
Theranostics; 2020; 10(13):5704-5718. PubMed ID: 32483413
[No Abstract] [Full Text] [Related]
10. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350.
Cui X; Cao Z; Chen Q; Arjunaraja S; Snow AL; Snapper CM
Vaccine; 2016 Jul; 34(34):4050-5. PubMed ID: 27291087
[TBL] [Abstract][Full Text] [Related]
11. Subunit vaccine formulations based on recombinant envelope proteins of Chikungunya virus elicit balanced Th1/Th2 response and virus-neutralizing antibodies in mice.
Khan M; Dhanwani R; Rao PV; Parida M
Virus Res; 2012 Aug; 167(2):236-46. PubMed ID: 22610133
[TBL] [Abstract][Full Text] [Related]
12. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule.
Tanner JE; Coinçon M; Leblond V; Hu J; Fang JM; Sygusch J; Alfieri C
J Virol; 2015 May; 89(9):4932-41. PubMed ID: 25694592
[TBL] [Abstract][Full Text] [Related]
13. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults.
Sokal EM; Hoppenbrouwers K; Vandermeulen C; Moutschen M; Léonard P; Moreels A; Haumont M; Bollen A; Smets F; Denis M
J Infect Dis; 2007 Dec; 196(12):1749-53. PubMed ID: 18190254
[TBL] [Abstract][Full Text] [Related]
14. Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells.
Bu W; Joyce MG; Nguyen H; Banh DV; Aguilar F; Tariq Z; Yap ML; Tsujimura Y; Gillespie RA; Tsybovsky Y; Andrews SF; Narpala SR; McDermott AB; Rossmann MG; Yasutomi Y; Nabel GJ; Kanekiyo M; Cohen JI
Immunity; 2019 May; 50(5):1305-1316.e6. PubMed ID: 30979688
[TBL] [Abstract][Full Text] [Related]
15. DNA-mediated immunization of glycoprotein 350 of Epstein-Barr virus induces the effective humoral and cellular immune responses against the antigen.
Jung S; Chung YK; Chang SH; Kim J; Kim HR; Jang HS; Lee JC; Chung GH; Jang YS
Mol Cells; 2001 Aug; 12(1):41-9. PubMed ID: 11561729
[TBL] [Abstract][Full Text] [Related]
16. Construction of Epstein-Bar virus cocktail peptide fused with Fcγ of IgG: as a potential delivery system for vaccine development.
Amel Jamehdar S; Tabaei S; Mashkani B; Karimi R; Motallebnezhad M; Esmaili A
Bioengineered; 2019 Dec; 10(1):689-696. PubMed ID: 31739735
[TBL] [Abstract][Full Text] [Related]
17. Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector.
Finerty S; Tarlton J; Mackett M; Conway M; Arrand JR; Watkins PE; Morgan AJ
J Gen Virol; 1992 Feb; 73 ( Pt 2)():449-53. PubMed ID: 1311367
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults.
Moutschen M; Léonard P; Sokal EM; Smets F; Haumont M; Mazzu P; Bollen A; Denamur F; Peeters P; Dubin G; Denis M
Vaccine; 2007 Jun; 25(24):4697-705. PubMed ID: 17485150
[TBL] [Abstract][Full Text] [Related]
19. Efficient production of recombinant glycoprotein D of herpes simplex virus type 2 in Pichia pastoris and its protective efficacy against viral challenge in mice.
Wang M; Jiang S; Zhou L; Wang C; Mao R; Ponnusamy M
Arch Virol; 2017 Mar; 162(3):701-711. PubMed ID: 27868164
[TBL] [Abstract][Full Text] [Related]
20. Recombinant gp90 protein expressed in Pichia pastoris induces a protective immune response against reticuloendotheliosis virus in chickens.
Li K; Gao H; Gao L; Qi X; Gao Y; Qin L; Wang Y; Wang X
Vaccine; 2012 Mar; 30(13):2273-81. PubMed ID: 22314135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
